Infectious Mononucleosis Clinical Trial
Official title:
Mikrobiologi Ved svær Akut Tonsillit, peritonsillær Phlegmone og infektiøs Mononukleose
Prospective, observational study of the microbiology of patients referred to a tertiary care center with severe acute tonsillitis, peritonsillar cellulitis, or infectious mononucleosis.
Status | Not yet recruiting |
Enrollment | 350 |
Est. completion date | December 2021 |
Est. primary completion date | May 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 15 Years to 40 Years |
Eligibility |
Inclusion Criteria: 1. Patients referred to our tertiary care center with acute tonsillitis with or without signs of peritonsillar cellulitis and with or without infectious mononucleosis. 2. Center Score 3 or 4. Exclusion Criteria: 1. Abscess formation. 2. Previous tonsillectomy. |
Observational Model: Case Control, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Denmark | Aarhus University Hospital | Aarhus |
Lead Sponsor | Collaborator |
---|---|
Tejs Ehlers Klug | Statens Serum Institut |
Denmark,
Ehlers Klug T, Rusan M, Fuursted K, Ovesen T. Fusobacterium necrophorum: most prevalent pathogen in peritonsillar abscess in Denmark. Clin Infect Dis. 2009 Nov 15;49(10):1467-72. doi: 10.1086/644616. — View Citation
Klug TE, Henriksen JJ, Fuursted K, Ovesen T. Significant pathogens in peritonsillar abscesses. Eur J Clin Microbiol Infect Dis. 2011 May;30(5):619-27. doi: 10.1007/s10096-010-1130-9. Epub 2010 Dec 22. — View Citation
Klug TE, Henriksen JJ, Rusan M, Fuursted K, Krogfelt KA, Ovesen T, Struve C. Antibody development to Fusobacterium necrophorum in patients with peritonsillar abscess. Eur J Clin Microbiol Infect Dis. 2014 Oct;33(10):1733-9. doi: 10.1007/s10096-014-2130-y. Epub 2014 May 9. — View Citation
Klug TE. Incidence and microbiology of peritonsillar abscess: the influence of season, age, and gender. Eur J Clin Microbiol Infect Dis. 2014 Jul;33(7):1163-7. doi: 10.1007/s10096-014-2052-8. Epub 2014 Jan 29. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Prevalence of Fusobacterium necrophorum in throat swab cultures | At acute consultation (day 0) | No | |
Secondary | Number of participants with recurrent throat infections (questionnaire) | Six months after acute consultation | No | |
Secondary | Number of participants without eradication of throat pathogens (throat cultures) | "Throat pathogens": Fusobacterium necrophorum, Beta-hemolytical streptococci, A. hemolyticum | 14-28 days after acute consultation | No |
Secondary | Number of participants with complications of severe acute tonsillitis, peritonsillar cellulitis, and infectious mononucleosis | "Complications": admission, abscess Development, change of antibiotic treatment | 14-28 days after acute consultation | No |
Secondary | Prevalence of anti-Fusobacterium necrophorum antibody Development (two-fold or higher increase in antibody level) (blood samples) | Comparison of the prevalence of antibody Development (two-fold or higher increase in antibody level) between patients with recovery of Fusobacterium necrophorum in throat swabs versus patients without recovery of Fusobacterium necrophorum in throat swabs | In acute and convalescent sera (day 0 and 14-28) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05683834 -
Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons
|
Phase 1/Phase 2 | |
Completed |
NCT00575185 -
Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04645147 -
Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection
|
Phase 1 | |
Completed |
NCT06002802 -
Study on Infectious Mononucleosis in Munich
|
||
Withdrawn |
NCT04138875 -
A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)
|
Phase 2 | |
Terminated |
NCT00598988 -
Acupuncture for Infectious Mononucleosis Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05225493 -
HIV Indicator Diseases in Hospital and Primary Care
|
||
Completed |
NCT00274404 -
Controlled Trial of Valacyclovir in Infectious Mononucleosis
|
Phase 1/Phase 2 | |
Terminated |
NCT02463669 -
The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department
|